184 related articles for article (PubMed ID: 7662849)
1. Assessment of individual and population bioequivalence using the probability that bioavailabilities are similar.
Schall R
Biometrics; 1995 Jun; 51(2):615-26. PubMed ID: 7662849
[TBL] [Abstract][Full Text] [Related]
2. On population and individual bioequivalence.
Schall R; Luus HG
Stat Med; 1993 Jun; 12(12):1109-24. PubMed ID: 8210816
[TBL] [Abstract][Full Text] [Related]
3. A three-step procedure for assessing bioequivalence in the general mixed model framework.
Vuorinen J; Turunen J
Stat Med; 1996 Dec; 15(24):2635-55. PubMed ID: 8981677
[TBL] [Abstract][Full Text] [Related]
4. Bioavailability of two oral-tablet and two oral-suspension formulations of naproxen sodium/paracetamol (acetaminophen): single-dose, randomized, open-label, two-period crossover comparisons in healthy Mexican adult subjects.
Palma-Aguirre JA; Villalpando-Hernández J; Novoa-Heckel G; Oliva I; Cariño L; López-Bojórquez E; Burke-Fraga V; Namur S; González-de la Parra M
Clin Ther; 2009 Feb; 31(2):399-410. PubMed ID: 19302912
[TBL] [Abstract][Full Text] [Related]
5. Types of bioequivalence and related statistical considerations.
Hauck WW; Anderson S
Int J Clin Pharmacol Ther Toxicol; 1992 May; 30(5):181-7. PubMed ID: 1592546
[TBL] [Abstract][Full Text] [Related]
6. Assessment of bioequivalence using a multiplicative model.
Chow SC; Peace KE; Shao J
J Biopharm Stat; 1991; 1(2):193-203. PubMed ID: 1844696
[TBL] [Abstract][Full Text] [Related]
7. On TIER method for assessment of individual bioequivalence.
Ju HL
J Biopharm Stat; 1997 Mar; 7(1):63-85. PubMed ID: 9056589
[TBL] [Abstract][Full Text] [Related]
8. [Review and use of decision rules for bioequivalence trials].
Nicolas P; Tod M; Petitjean O
Therapie; 1993; 48(1):15-22. PubMed ID: 8356540
[TBL] [Abstract][Full Text] [Related]
9. Sample size determination for bioequivalence assessment by means of confidence intervals.
Diletti E; Hauschke D; Steinijans VW
Int J Clin Pharmacol Ther Toxicol; 1992; 30 Suppl 1():S51-8. PubMed ID: 1601532
[TBL] [Abstract][Full Text] [Related]
10. Mean difference vs. variability reduction: tradeoffs in aggregate measures for individual bioequivalence. FDA Individual Bioequivalence Working Group.
Hauck WW; Chen ML; Hyslop T; Patnaik R; Schuirmann D; Williams R
Int J Clin Pharmacol Ther; 1996 Dec; 34(12):535-41. PubMed ID: 8996848
[TBL] [Abstract][Full Text] [Related]
11. [Relative bioavailability of paracetamol in suppositories preparations in comparison to tablets].
Blume H; Ali SL; Elze M; Krämer J; Wendt G; Scholz ME
Arzneimittelforschung; 1994 Dec; 44(12):1333-8. PubMed ID: 7848353
[TBL] [Abstract][Full Text] [Related]
12. A method for the evaluation of individual bioequivalence.
Endrenyi L
Int J Clin Pharmacol Ther; 1994 Sep; 32(9):497-508. PubMed ID: 7820334
[TBL] [Abstract][Full Text] [Related]
13. Assessment of individual agreements with repeated measurements based on generalized confidence intervals.
Quiroz J; Burdick RK
J Biopharm Stat; 2009; 19(2):345-59. PubMed ID: 19212885
[TBL] [Abstract][Full Text] [Related]
14. Alternative confidence intervals for the assessment of bioequivalence in four-period cross-over designs.
Quiroz J; Ting N; Wei GC; Burdick RK
Stat Med; 2002 Jul; 21(13):1825-47. PubMed ID: 12111892
[TBL] [Abstract][Full Text] [Related]
15. Asymmetry of the mean-variability tradeoff raises questions about the model in investigations of individual bioequivalence.
Endrenyi L; Hao Y
Int J Clin Pharmacol Ther; 1998 Aug; 36(8):450-7. PubMed ID: 9726700
[TBL] [Abstract][Full Text] [Related]
16. Sample size determination for bioequivalence assessment by means of confidence intervals.
Diletti E; Hauschke D; Steinijans VW
Int J Clin Pharmacol Ther Toxicol; 1991 Jan; 29(1):1-8. PubMed ID: 2004861
[TBL] [Abstract][Full Text] [Related]
17. Sample size considerations for assessing individual bioequivalence based on the method of tolerance intervals.
Esinhart JD; Chinchilli VM
Int J Clin Pharmacol Ther; 1994 Jan; 32(1):26-32. PubMed ID: 8199749
[TBL] [Abstract][Full Text] [Related]
18. Extension to the use of tolerance intervals for the assessment of individual bioequivalence.
Esinhart JD; Chinchilli VM
J Biopharm Stat; 1994 Mar; 4(1):39-52. PubMed ID: 8019583
[TBL] [Abstract][Full Text] [Related]
19. Assessment of selection bias in estimates of relative bioavailability and intrasubject variability from bioequivalence evaluations.
Wang Y
J Biopharm Stat; 2000 Aug; 10(3):407-24. PubMed ID: 10959920
[TBL] [Abstract][Full Text] [Related]
20. On confidence limits associated with Chow and Shao's joint confidence region approach for assessment of bioequivalence.
Hsu HC; Lu HL
J Biopharm Stat; 1997 Mar; 7(1):125-34. PubMed ID: 9056593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
